Omalizumab for Chronic Allergic Bronchopulmonary Aspergillosis: a randomised, placebo-controlled crossover trial
Phase 2
Completed
- Conditions
- Allergic Bronchopulmonary AspergillosisRespiratory - Other respiratory disorders / diseasesInflammatory and Immune System - Other inflammatory or immune system disorders
- Registration Number
- ACTRN12613000278730
- Lead Sponsor
- Jo Douglass
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Diagnosis of chronic allergic bronchopulmonary aspergillosis
Symptomatic despite maximal doses of inhaled asthma treatments and regular oral corticosteroids if required.
Previous asthma diagnosis
Elevated serum total IgE (>400kU/L)
Proximal bronchiectasis on CT scan
Detectable specific IgE to Aspergillus antigens
Exclusion Criteria
Recent use of anti-fungal therapy (8 weeks)
Exacerbation requiring increased oral corticosteroid in the past 6 weeks.
Cystic fibrosis
Pregnancy and lactation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Exacerbations measured by increased symptoms and a significant decrease in lung function and treated by the managing clinicians with escalation of prednisolone dose.[4 months]
- Secondary Outcome Measures
Name Time Method